{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T08:27:13Z","timestamp":1790497633310,"version":"4.1.0"},"reference-count":82,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T00:00:00Z","timestamp":1543795200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004710","name":"Fondazione Umberto Veronesi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG-15615"],"award-info":[{"award-number":["IG-15615"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG-20055"],"award-info":[{"award-number":["IG-20055"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007109","name":"Universit\u00e0 degli Studi di Ferrara","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007109","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.omtn.2018.11.018","type":"journal-article","created":{"date-parts":[[2018,12,6]],"date-time":"2018-12-06T05:27:26Z","timestamp":1544074046000},"page":"239-250","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["MicroRNA-Based Prophylaxis in a Mouse Model of Cirrhosis and Liver Cancer"],"prefix":"10.1016","volume":"14","author":[{"given":"Elisa","family":"Callegari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Domenicali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram Charan","family":"Shankaraiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucilla","family":"D\u2019Abundo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Guerriero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinando","family":"Giannone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Baldassarre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Bassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahaeldin K.","family":"Elamin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Zagatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Ferracin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Fornari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Altavilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella","family":"Blandamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico Maria","family":"Silini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Gramantieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Sabbioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Negrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2018.11.018_bib1","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int. J. Cancer"},{"issue":"5, Suppl 1","key":"10.1016\/j.omtn.2018.11.018_bib2","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1053\/j.gastro.2004.09.014","article-title":"Hepatocellular carcinoma in cirrhosis: incidence and risk factors","volume":"127","author":"Fattovich","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.omtn.2018.11.018_bib3","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.cld.2007.02.006","article-title":"Non-alcoholic steatohepatitis and cancer","volume":"11","author":"Bugianesi","year":"2007","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.omtn.2018.11.018_bib4","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1002\/hep.23594","article-title":"Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection","volume":"51","author":"Starley","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.omtn.2018.11.018_bib5","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.24199","article-title":"Management of hepatocellular carcinoma: an update","volume":"53","author":"Bruix","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.omtn.2018.11.018_bib6","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtn.2018.11.018_bib7","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.ejca.2011.12.006","article-title":"Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial","volume":"48","author":"Cheng","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.omtn.2018.11.018_bib8","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1158\/1078-0432.CCR-13-0547","article-title":"Hepatocellular carcinoma: reasons for\u00a0phase III failure and novel perspectives on trial design","volume":"20","author":"Llovet","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omtn.2018.11.018_bib9","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s12328-016-0670-7","article-title":"Current status and future prospects of chemotherapy for advanced hepatocellular carcinoma","volume":"9","author":"Moriguchi","year":"2016","journal-title":"Clin. J. Gastroenterol."},{"key":"10.1016\/j.omtn.2018.11.018_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11523-016-0452-7","article-title":"Targeting multiple oncogenic pathways for the treatment of hepatocellular carcinoma","volume":"12","author":"Swamy","year":"2017","journal-title":"Target. Oncol."},{"key":"10.1016\/j.omtn.2018.11.018_bib11","doi-asserted-by":"crossref","first-page":"15004","DOI":"10.1038\/sigtrans.2015.4","article-title":"The role of MicroRNAs in human cancer","volume":"1","author":"Peng","year":"2016","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.omtn.2018.11.018_bib12","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.canlet.2017.04.007","article-title":"microRNAs as cancer therapeutics: A step closer to clinical application","volume":"407","author":"Catela Ivkovic","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.omtn.2018.11.018_bib13","doi-asserted-by":"crossref","first-page":"5073","DOI":"10.1158\/1078-0432.CCR-09-0092","article-title":"MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality","volume":"15","author":"Gramantieri","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omtn.2018.11.018_bib14","doi-asserted-by":"crossref","first-page":"5651","DOI":"10.1038\/onc.2008.178","article-title":"MiR-221 controls CDKN1C\/p57 and CDKN1B\/p27 expression in human hepatocellular carcinoma","volume":"27","author":"Fornari","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.omtn.2018.11.018_bib15","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ccr.2009.10.014","article-title":"miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation","volume":"16","author":"Garofalo","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omtn.2018.11.018_bib16","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1002\/hep.25747","article-title":"Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model","volume":"56","author":"Callegari","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.omtn.2018.11.018_bib17","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1038\/sj.onc.1209283","article-title":"Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues","volume":"25","author":"Murakami","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.omtn.2018.11.018_bib18","doi-asserted-by":"crossref","first-page":"5184","DOI":"10.1158\/0008-5472.CAN-10-0145","article-title":"MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells","volume":"70","author":"Fornari","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.omtn.2018.11.018_bib19","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12929-016-0295-7","article-title":"miR-199a-3p inhibits cell proliferation and induces apoptosis by targeting YAP1, suppressing Jagged1-Notch signaling in human hepatocellular carcinoma","volume":"23","author":"Ren","year":"2016","journal-title":"J.\u00a0Biomed. Sci."},{"key":"10.1016\/j.omtn.2018.11.018_bib20","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.omtn.2018.04.002","article-title":"miR-199a-3p Modulates MTOR and PAK4 Pathways and Inhibits Tumor Growth in a Hepatocellular Carcinoma Transgenic Mouse Model","volume":"11","author":"Callegari","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2018.11.018_bib21","doi-asserted-by":"crossref","first-page":"3953","DOI":"10.1158\/1078-0432.CCR-16-1464","article-title":"In hepatocellular carcinoma miR-221 modulates Sorafenib resistance through inhibition of caspase-3-mediated apoptosis","volume":"23","author":"Fornari","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omtn.2018.11.018_bib22","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ccr.2011.01.001","article-title":"Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a\/b-3p as therapeutic target for hepatocellular carcinoma","volume":"19","author":"Hou","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omtn.2018.11.018_bib23","doi-asserted-by":"crossref","first-page":"e73964","DOI":"10.1371\/journal.pone.0073964","article-title":"Anti-tumor activity of a miR-199-dependent oncolytic adenovirus","volume":"8","author":"Callegari","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.omtn.2018.11.018_bib24","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.jhep.2008.01.008","article-title":"Experimental models of hepatocellular carcinoma","volume":"48","author":"Newell","year":"2008","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.omtn.2018.11.018_bib25","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1365-2613.2009.00656.x","article-title":"Experimental mouse models for hepatocellular carcinoma research","volume":"90","author":"Heindryckx","year":"2009","journal-title":"Int. J. Exp. Pathol."},{"key":"10.1016\/j.omtn.2018.11.018_bib26","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/nrgastro.2011.196","article-title":"Hepatocellular carcinoma: insight from animal models","volume":"9","author":"Li","year":"2011","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.omtn.2018.11.018_bib27","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1590\/S0102-86502012000800013","article-title":"Review of experimental models for inducing hepatic cirrhosis by bile duct ligation and carbon tetrachloride injection","volume":"27","author":"Marques","year":"2012","journal-title":"Acta Cir. Bras."},{"key":"10.1016\/j.omtn.2018.11.018_bib28","doi-asserted-by":"crossref","first-page":"4167","DOI":"10.3748\/wjg.v11.i27.4167","article-title":"Comparison of murine cirrhosis models induced by hepatotoxin administration and common bile duct ligation","volume":"11","author":"Chang","year":"2005","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.omtn.2018.11.018_bib29","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.jhep.2009.09.008","article-title":"A novel model of CCl4-induced cirrhosis with ascites in the mouse","volume":"51","author":"Domenicali","year":"2009","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.omtn.2018.11.018_bib30","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.4161\/cbt.6.10.4683","article-title":"Identification of candidate biomarkers for hepatocellular carcinoma through pre-cancerous expression analysis in an HBx transgenic mouse","volume":"6","author":"Sun","year":"2007","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.omtn.2018.11.018_bib31","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1038\/modpathol.3800436","article-title":"The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma","volume":"18","author":"Yamauchi","year":"2005","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.omtn.2018.11.018_bib32","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1665-2681(19)30903-2","article-title":"Stem cell and hepatocyte proliferation in hepatitis C cirrhosis and hepatocellular carcinoma: transplant implications","volume":"13","author":"Behnke","year":"2013","journal-title":"Ann. Hepatol."},{"key":"10.1016\/j.omtn.2018.11.018_bib33","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1440-1746.1992.tb00940.x","article-title":"Carbon tetrachloride induced cirrhosis in rats: a useful tool for investigating the pathogenesis of ascites in chronic liver disease","volume":"7","author":"Jim\u00e9nez","year":"1992","journal-title":"J.\u00a0Gastroenterol. Hepatol."},{"key":"10.1016\/j.omtn.2018.11.018_bib34","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jhep.2005.01.034","article-title":"A novel sodium overload test predicting ascites decompensation in rats with CCl4-induced cirrhosis","volume":"43","author":"Domenicali","year":"2005","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.omtn.2018.11.018_bib35","first-page":"70","article-title":"Expression of ErbB receptor proteins and TGF-alpha during diethylnitrosamine-induced hepatocarcinogenesis in the rat liver","volume":"13","author":"Lee","year":"2007","journal-title":"Korean J. Hepatol."},{"key":"10.1016\/j.omtn.2018.11.018_bib36","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/hep.20538","article-title":"Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis","volume":"41","author":"Schiffer","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.omtn.2018.11.018_bib37","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3727\/096504013X13747716581336","article-title":"Two-stage model of chemically induced hepatocellular carcinoma in mouse","volume":"20","author":"Luo","year":"2013","journal-title":"Oncol. Res."},{"key":"10.1016\/j.omtn.2018.11.018_bib38","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/toxsci\/kfs342","article-title":"Molecular mechanisms of fibrosis-associated promotion of liver carcinogenesis","volume":"132","author":"Uehara","year":"2013","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.omtn.2018.11.018_bib39","first-page":"14.30.1","article-title":"The DEN and CCl4 -Induced Mouse Model of Fibrosis and Inflammation-Associated Hepatocellular Carcinoma","volume":"66","author":"Uehara","year":"2014","journal-title":"Curr. Protoc. Pharmacol."},{"key":"10.1016\/j.omtn.2018.11.018_bib40","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/nprot.2015.080","article-title":"An orthotopic mouse model of hepatocellular carcinoma with underlying liver cirrhosis","volume":"10","author":"Reiberger","year":"2015","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.omtn.2018.11.018_bib41","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12876-016-0423-6","article-title":"Development of a transgenic mouse model of hepatocellular carcinoma with a liver fibrosis background","volume":"16","author":"Chung","year":"2016","journal-title":"BMC Gastroenterol."},{"key":"10.1016\/j.omtn.2018.11.018_bib42","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1002\/j.2040-4603.2013.tb00529.x","article-title":"Hepatic stellate cells and liver fibrosis","volume":"3","author":"Puche","year":"2013","journal-title":"Compr. Physiol."},{"key":"10.1016\/j.omtn.2018.11.018_bib43","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/jcp.25879","article-title":"TGF\u03b2 signaling and the control of myofibroblast differentiation: Implications for chronic inflammatory disorders","volume":"233","author":"Carthy","year":"2018","journal-title":"J.\u00a0Cell. Physiol."},{"key":"10.1016\/j.omtn.2018.11.018_bib44","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s12013-015-0693-6","article-title":"Transforming Growth Factor \u03b21 Promotes Migration and Invasion of Human Hepatocellular Carcinoma Cells Via Up-Regulation of Connective Tissue Growth Factor","volume":"73","author":"Liu","year":"2015","journal-title":"Cell Biochem. Biophys."},{"key":"10.1016\/j.omtn.2018.11.018_bib45","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.jhep.2017.09.016","article-title":"Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine","volume":"68","author":"Fujiwara","year":"2018","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.omtn.2018.11.018_bib46","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/cld.568","article-title":"Statins and metformin for chemoprevention of hepatocellular carcinoma","volume":"8","author":"Choi","year":"2016","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.omtn.2018.11.018_bib47","doi-asserted-by":"crossref","first-page":"e0127967","DOI":"10.1371\/journal.pone.0127967","article-title":"Anti-tumor effects of metformin in animal models of hepatocellular carcinoma: a systematic review and meta-analysis","volume":"10","author":"Li","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.omtn.2018.11.018_bib48","article-title":"An Overview of Natural Plant Products in the Treatment of Hepatocellular Carcinoma","author":"Rawat","year":"2018","journal-title":"Anticancer Agents Med. Chem."},{"key":"10.1016\/j.omtn.2018.11.018_bib49","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1007\/s11095-010-0144-4","article-title":"Suppression of the inflammatory cascade is implicated in resveratrol chemoprevention of experimental hepatocarcinogenesis","volume":"27","author":"Bishayee","year":"2010","journal-title":"Pharm. Res."},{"key":"10.1016\/j.omtn.2018.11.018_bib50","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.intimp.2017.01.016","article-title":"Curcumin ameliorates liver damage and progression of NASH in NASH-HCC mouse model possibly by modulating HMGB1-NF-\u03baB translocation","volume":"44","author":"Afrin","year":"2017","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.omtn.2018.11.018_bib51","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1080\/17474124.2018.1530110","article-title":"An update on the recent advances in antifibrotic therapy","volume":"12","author":"Tacke","year":"2018","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.omtn.2018.11.018_bib52","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/j.1349-7006.2006.00237.x","article-title":"Chemoprevention of spontaneous development of hepatocellular carcinomas in fatty liver Shionogi mice by a cyclooxygenase-2 inhibitor","volume":"97","author":"Liu","year":"2006","journal-title":"Cancer Sci."},{"key":"10.1016\/j.omtn.2018.11.018_bib53","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/hep.22990","article-title":"S-adenosylmethionine in the chemoprevention and treatment of hepatocellular carcinoma in a rat model","volume":"50","author":"Lu","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.omtn.2018.11.018_bib54","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/cdd.2014.136","article-title":"MicroRNAs in liver cancer: a model for investigating pathogenesis and novel therapeutic approaches","volume":"22","author":"Callegari","year":"2015","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.omtn.2018.11.018_bib55","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2174\/2211536606666170710183039","article-title":"MicroRNAs-based Therapy: A Novel and Promising Strategy for Cancer Treatment","volume":"6","author":"Moles","year":"2017","journal-title":"MicroRNA"},{"key":"10.1016\/j.omtn.2018.11.018_bib56","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1073\/pnas.0907904107","article-title":"miR-221 overexpression contributes to liver tumorigenesis","volume":"107","author":"Pineau","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2018.11.018_bib57","doi-asserted-by":"crossref","first-page":"7608","DOI":"10.1158\/0008-5472.CAN-11-1144","article-title":"miR-221 silencing blocks hepatocellular carcinoma and promotes survival","volume":"71","author":"Park","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.omtn.2018.11.018_bib58","first-page":"4764","article-title":"miR-221 promotes growth and invasion of hepatocellular carcinoma cells by constitutive activation of NF\u03baB","volume":"8","author":"Liu","year":"2016","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.omtn.2018.11.018_bib59","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s12013-011-9263-8","article-title":"Lentivirus-mediated overexpression of microRNA-199a inhibits cell proliferation of human hepatocellular carcinoma","volume":"62","author":"Jia","year":"2012","journal-title":"Cell Biochem. Biophys."},{"key":"10.1016\/j.omtn.2018.11.018_bib60","doi-asserted-by":"crossref","first-page":"e2706","DOI":"10.1038\/cddis.2017.123","article-title":"MiRNA199a-3p suppresses tumor growth, migration, invasion and angiogenesis in hepatocellular carcinoma by targeting VEGFA, VEGFR1, VEGFR2, HGF and MMP2","volume":"8","author":"Ghosh","year":"2017","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.omtn.2018.11.018_bib61","first-page":"2457","article-title":"MicroRNA-199a-3p inhibits tumorigenesis of hepatocellular carcinoma cells by targeting ZHX1\/PUMA signal","volume":"9","author":"Guan","year":"2017","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.omtn.2018.11.018_bib62","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1002\/hep.29643","article-title":"Targeted delivery of microRNA-199a-3p using self-assembled dipeptide nanoparticles efficiently reduces hepatocellular carcinoma in mice","volume":"67","author":"Varshney","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.omtn.2018.11.018_bib63","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.gene.2016.12.014","article-title":"Structure, biochemistry, and biology of PAK kinases","volume":"605","author":"Kumar","year":"2017","journal-title":"Gene"},{"key":"10.1016\/j.omtn.2018.11.018_bib64","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1128\/MCB.01286-08","article-title":"Pak4, a novel Gab1 binding partner, modulates cell migration and invasion by the Met receptor","volume":"29","author":"Paliouras","year":"2009","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.omtn.2018.11.018_bib65","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1042\/bj20031041","article-title":"Rho GTPases have diverse effects on the organization of the actin filament system","volume":"377","author":"Aspenstr\u00f6m","year":"2004","journal-title":"Biochem. J."},{"key":"10.1016\/j.omtn.2018.11.018_bib66","doi-asserted-by":"crossref","first-page":"8778","DOI":"10.18632\/oncotarget.2398","article-title":"p-21 activated kinase 4 promotes proliferation and survival of pancreatic cancer cells through AKT- and ERK-dependent activation of NF-\u03baB pathway","volume":"5","author":"Tyagi","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.omtn.2018.11.018_bib67","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1242\/jcs.00080","article-title":"PAK4 is activated via PI3K in HGF-stimulated epithelial cells","volume":"115","author":"Wells","year":"2002","journal-title":"J.\u00a0Cell Sci."},{"key":"10.1016\/j.omtn.2018.11.018_bib68","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/bs.acr.2016.01.002","article-title":"PAKs in Human Cancer Progression: From Inception to Cancer Therapeutic to Future Oncobiology","volume":"130","author":"Kumar","year":"2016","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.omtn.2018.11.018_bib69","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1158\/1078-0432.CCR-12-3433","article-title":"Functional analysis of genes in regions commonly amplified in high-grade serous and endometrioid ovarian cancer","volume":"19","author":"Davis","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omtn.2018.11.018_bib70","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nature05610","article-title":"Patterns of somatic mutation in human cancer genomes","volume":"446","author":"Greenman","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2018.11.018_bib71","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1038\/onc.2012.233","article-title":"PAK4 kinase activity and somatic mutation promote carcinoma cell motility and influence inhibitor sensitivity","volume":"32","author":"Whale","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.omtn.2018.11.018_bib72","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/436792a","article-title":"Colorectal cancer: mutations in a signalling pathway","volume":"436","author":"Parsons","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2018.11.018_bib73","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1002\/jcp.24351","article-title":"mTOR signaling for biological control and cancer","volume":"228","author":"Alayev","year":"2013","journal-title":"J.\u00a0Cell. Physiol."},{"key":"10.1016\/j.omtn.2018.11.018_bib74","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1053\/j.gastro.2015.05.061","article-title":"Genetic Landscape and Biomarkers of Hepatocellular Carcinoma","volume":"149","author":"Zucman-Rossi","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.omtn.2018.11.018_bib75","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/nrc3037","article-title":"PTEN loss in the continuum of common cancers, rare syndromes and mouse models","volume":"11","author":"Hollander","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.omtn.2018.11.018_bib76","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1172\/JCI20513","article-title":"Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas","volume":"113","author":"Horie","year":"2004","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.omtn.2018.11.018_bib77","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.4161\/cc.6.22.4900","article-title":"Diverse ways to control p27Kip1 function: miRNAs come into play","volume":"6","author":"le Sage","year":"2007","journal-title":"Cell Cycle"},{"key":"10.1016\/j.omtn.2018.11.018_bib78","first-page":"465","article-title":"Ultrasonography as the Gold Standard for In\u00a0Vivo Volumetric Determination of Chemically-induced Mammary Tumors","volume":"30","author":"Faustino-Rocha","year":"2016","journal-title":"In\u00a0Vivo"},{"key":"10.1016\/j.omtn.2018.11.018_bib79","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1158\/1078-0432.CCR-12-3191","article-title":"Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia","volume":"19","author":"Huang","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omtn.2018.11.018_bib80","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1002\/hep.1840220341","article-title":"Terminology of nodular hepatocellular lesions","volume":"22","author":"Wanless","year":"1995","journal-title":"Hepatology"},{"key":"10.1016\/j.omtn.2018.11.018_bib81","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/hep.22709","article-title":"Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia","volume":"49","author":"Neoplasia","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.omtn.2018.11.018_bib82","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1158\/1055-9965.EPI-14-0503","article-title":"Quantification of circulating miRNAs by droplet digital PCR: comparison of EvaGreen- and TaqMan-based chemistries","volume":"23","author":"Miotto","year":"2014","journal-title":"Cancer Epidemiol. Biomarkers Prev."}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253118303147?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253118303147?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T17:09:11Z","timestamp":1751044151000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253118303147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":82,"alternative-id":["S2162253118303147"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2018.11.018","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MicroRNA-Based Prophylaxis in a Mouse Model of Cirrhosis and Liver Cancer","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2018.11.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Author(s).","name":"copyright","label":"Copyright"}]}}